Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

by B2i | Oct 27, 2022 | Press Releases

JUPITER, Fla., Oct. 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

by B2i | Oct 27, 2022 | Press Releases

JUPITER, Fla., Oct. 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

by B2i | Oct 4, 2022 | Press Releases

JUPITER, Fla., Oct. 04, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Updates Market on Recent Scientific Achievements

by B2i | Sep 13, 2022 | Press Releases

JUPITER, Fla., Sept. 13, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Present at Upcoming Industry and Investor Events in September

by B2i | Sep 8, 2022 | Press Releases

JUPITER, Fla., Sept. 08, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...